^
Association details:
| Biomarker: | MSI-H/dMMR + KDR overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev. Add to Collection
Published date:
01/18/2022
Excerpt:
However, high VEGFR was associated with bev benefit in dMMR pts p=0.0012, HR=0.08 [95% CI; 0.025-0.224], n=117) but not in pts with pMMR (n=555) (int p=0.03)....High VEGFR is associated with bev benefit in dMMR pts.
DOI:
10.1200/JCO.2022.40.4_suppl.140
